New gadget aims to sharpen MRI readings for pancreatic cancer
NCT ID NCT04588025
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a small, portable device called P4 that sits inside an MRI scanner to improve the accuracy of scans for pancreatic cancer. Researchers want to see if it can reduce errors when measuring blood flow in tumors, which helps doctors know if treatment is working. The trial includes 5 healthy volunteers and 50 pancreatic cancer patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Point-of-care Portable Perfusion Phantom (P4) device
- What this could lead to
- If successful, this device could make MRI scans more reliable for tracking whether pancreatic cancer treatments are working, helping doctors adjust therapy sooner.
- What could go wrong
- This is a small, early-stage study focused on measurement accuracy, not treatment. The device may not improve outcomes or be adopted widely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 55 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2020
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Healthy Volunteer - a small number of healthy volunteers (5) will be used as the control group. Inclusion Criteria: * Targeted/planned enrollment in the study will include all racial/ethnic groups with no groups excluded on the basis of race, ethnicity or gender. * Participants should be 19 years of age or older * Participants should not have any known major health problems including but not limited to cancers, heart diseases, diabetes, high blood pressure and/or cholesterol, stroke, respiratory problems, and arthritis. Exclusion Criteria: * Participants having any known major health problems will be excluded. * Participants with safety contraindications to MRI examination (determined by standard clinical screening). * Participants on hemodialysis or with acute renal failure will be excluded. (Participants on hemodialysis and those with renal failure who receive intravenous gadolinium may be at increased risk for a condition called Nephrogenic systemic fibrosis/ Nephrogenic fibrosing dystrophy and thus will be excluded.) * Participants may not be pregnant or lactating. * Participants may not father a child while on this study as the treatment may indirectly affect an unborn child. * Unless participants cannot have children because of surgery or other medical reasons, participants must have been using an effective form of birth control before starting the study. * Participants must also agree to continue to use an effective form of birth control for 6 months after taking the study. Effective birth control includes birth control pills, patch, IUD (intrauterine device), condom, sponge, diaphragm with spermicide, or avoiding sexual activity that could cause pregnancy. Pancreatic Cancer Participants: Inclusion Criteria: * Patients having biopsy proven locally advanced pancreatic cancer will be asked to participate in this study. * Targeted/planned enrollment in the study will include all racial/ethnic groups, with no groups excluded on the basis of race, ethnicity or gender. * Participants should be 19 years of age or older. Exclusion Criteria: * Participants with safety contraindications to MRI examination (determined by standard clinical screening). * Participants on hemodialysis or with acute renal failure will be excluded. * Participants on hemodialysis and those with renal failure who receive intravenous gadolinium may be at increased risk for a condition called Nephrogenic systemic fibrosis/ Nephrogenic fibrosing dystrophy and thus will be excluded. * Participants may not be pregnant or lactating. * Participants may not father a child while on this study as the treatment may indirectly affect an unborn child. * Unless participants cannot have children because of surgery or other medical reasons, participants must have been using an effective form of birth control before starting the study. * Participants must also agree to continue to use an effective form of birth control for 6 months after taking the study. Effective birth control includes birth control pills, patch, IUD, condom, sponge, diaphragm with spermicide, or avoiding sexual activity that could cause pregnancy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pancreatic cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Drug combo crack pancreatic Cancer's defenses?
- Can a blood test before pancreatic surgery predict a dangerous leak?
- New chemo cocktail targets pancreatic cancer at every stage
- Bacteria-Based immunotherapy targets pancreatic tumors in first human test
- Can a new radiation machine cut breath holds for cancer patients?
- Two oral drugs join chemotherapy in a bid to shrink pancreatic tumors